"I believe that with Mike’s experience and leadership ... we will successfully expand our portfolio and become a global leader in life science research," said Dr. Xiaobo Wang, VP and CTO of ACEA.
SAN DIEGO, California (PRWEB) February 02, 2015
ACEA Biosciences, Inc., a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research, is pleased to announce Michael Honeysett as Vice President of Global Commercialization.
Mike Honeysett is a seasoned executive in the life science cellular analysis industry. He has created significant value for investors by assembling high-performing organizations, and combining them with targeted asset building strategies. Prior to joining ACEA Biosciences, Mr. Honeysett served as Chief Business Officer at Protelica, Inc. and has been instrumental in assessing new technologies and building early stage companies, as well as holding strategic and tactical leadership positions within two Fortune 500 companies. These responsibilities include Global Market Development Leader and Regional Sales Director for GE Healthcare, as well as VP of sales and marketing for Q3DM, an early pioneer in cellular Imaging. He has an extensive background in pharmacology, as well as biotechnical, pharmaceutical and clinical laboratory marketing.
“We are very excited that Mike accepted the VP position at ACEA Biosciences,” said Dr. Xiaobo Wang, VP and CTO of ACEA. “I believe that with Mike’s experience and leadership along with and ACEA's track record of innovation and excellence in the high performance cell analysis space, we will successfully expand our portfolio and become a global leader in life science research.”
“ACEA Biosciences has developed a full line of highly innovative technologies for cellular analysis, which I believe will dramatically accelerate the discovery process for new medicines and the improvement of clinical outcomes,” said Mike Honeysett. “The company is very customer centric and the people within the organization serve as true partners in research.” Mike went on to say, “The vision of the founders, coupled with the creativity and enthusiasm of the team towards the overall success of the company, the industry, and for each other, is truly a winning combination. The technology is fantastic and the team is a real joy to work with.”
About ACEA Biosciences
Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a privately held biotechnology company pioneering in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. With headquarters in San Diego, CA, ACEA has developed proprietary technology and launched its first product in 2004. Researchers are advancing their studies utilizing 1,300+ placed instruments for broad and diverse applications. The technology has been cited in over 600 peer reviewed publications. ACEA’s xCELLigence® and NovoCyte™ systems are used in pre-clinical drug discovery and development, toxicity, safety pharmacology, and basic academic research.
Visit http://www.aceabio.com to learn more about ACEA Biosciences.
ACEA Biosciences, Inc.
6779 Mesa Ridge Road, Suite100
San Diego, California 92121
1-866-308-2232 Toll Free
Contact for Media Inquiries:
Leyna Zhao, Ph.D.
Global Marketing Manager
Michael Honeysett, MBA
Vice President of Global Commercialization M